Commercial Strategy

Commercial strategy is the set of insights-driven choices that determine where a company competes, how it positions and prices its products, how it deploys commercial resources, and how it grows over multi-year horizons. In Animal Health and Life Sciences specifically, effective commercial strategy requires more than generic frameworks; it requires fluency in species-specific demand drivers, channel economics across veterinary clinics, distributors, retailers, and producers, prescriber and payer dynamics in human pharma, and the regulatory pathways shaping how products reach customers in each region. The output is a set of clear, actionable choices the leadership team can act on, supported by defensible data and primary research.

A typical commercial growth strategy engagement begins with a clear understanding of the client's portfolio, current performance, and competitive position, followed by structured analysis of market opportunities, customer segments, channel dynamics, and competitive threats. Output usually includes a multi-year strategic roadmap, prioritized growth initiatives, resource allocation recommendations, and an implementation plan with measurable milestones. Engagements typically run 8–14 weeks depending on geographic and portfolio scope, and the most valuable outputs translate directly into the client's annual planning cycle and operational priorities.

A product assessment is a structured evaluation of a single product or multi-product portfolio that combines market modeling, revenue forecasting, contribution analysis, and competitive scenario planning to support strategic decisions about investment, positioning, lifecycle management, or divestment. Companies typically commission product assessments before major investment decisions (R&D, in-licensing, expanded launch geographies), during portfolio reviews where capital allocation choices need to be made across assets, or in response to competitive threats such as generic entry or new product launches from competitors. Powered by our proprietary SC Analytics platform, our product assessments deliver defensible market and revenue projections grounded in real data.

A credible commercial launch plan integrates pricing strategy, competitive scenario analysis, segmentation and targeting, sales force sizing and territory design, multi-channel commercial model design, KOL engagement, and a clear definition of launch success metrics. In animal health, launch planning must additionally account for species-specific adoption curves, veterinary clinic and distributor dynamics, and regional regulatory differences. In human MedTech and pharma, hospital purchasing committees, payer access, and clinical adoption patterns shape the launch trajectory. The strongest launch plans are built before regulatory approval, refined through pre-launch market shaping, and adjusted based on early commercial signals after launch.

Innovation strategy focuses specifically on the choices a company makes about its long-cycle R&D investments, pipeline portfolio, and innovation capabilities - questions like which therapeutic areas or technology platforms to invest in, which assets to advance or de-prioritize, and how to balance internal R&D with external in-licensing and acquisition. Commercial strategy is broader, covering all the choices that drive market success across innovation, current portfolio, channels, pricing, and resource allocation. A strong innovation strategy is grounded in the same data-driven decision frameworks as commercial strategy, but with longer time horizons and greater attention to scientific, technical, and regulatory risk.

Transformation and change engagements support organizations through major commercial shifts - restructuring a business unit, integrating an acquisition, repositioning a portfolio, transitioning to new commercial models, or adapting to disruption such as generic entry or digital channel growth. These projects are typically longer than tactical strategy work, require strong client alignment and implementation support, and combine analytical rigor with the soft skills needed to land change inside an organization. Successful transformation work delivers measurable, lasting improvements rather than just recommendations on paper.

Stonehaven Cozmix Group works with corporate strategy teams, business unit leaders, commercial operations executives, and Private Equity sponsors across Animal Health, Life Sciences, and adjacent healthcare markets. Engagements span major manufacturers, mid-cap specialists, emerging innovators, and PE-backed companies. Clients typically engage us at decision points that carry meaningful commercial risk - a major product launch, a competitive disruption, a portfolio review, an acquisition or carve-out, or a strategic planning cycle that needs an independent, evidence-based perspective.